Artal Group Sa Position in Incyte Corp (INCY) Lifted by $23.20 Million

January 16, 2018 - By marketbeat

Investors sentiment increased to 1.04 in Q3 2017. Its up 0.02, from 1.02 in 2017Q2. It improved, as 39 investors sold INCY shares while 161 reduced holdings. 59 funds opened positions while 149 raised stakes. 188.97 million shares or 2.28% more from 184.77 million shares in 2017Q2 were reported. Walleye Trading, Minnesota-based fund reported 2,400 shares. Illinois-based Magnetar Financial has invested 0.01% in Incyte Corporation (NASDAQ:INCY). Nippon Life Insurance has invested 0.02% in Incyte Corporation (NASDAQ:INCY). Kentucky Retirement accumulated 10,436 shares. Nomura Holding Incorporated reported 17,628 shares or 0% of all its holdings. Polar Capital Limited Liability Partnership accumulated 47,500 shares. 6,817 were reported by Lpl Limited Co. 30,726 are owned by Daiwa Grp. Pictet Asset Limited stated it has 1.06M shares or 0.35% of all its holdings. California State Teachers Retirement System owns 0.07% invested in Incyte Corporation (NASDAQ:INCY) for 281,284 shares. Alliancebernstein Limited Partnership owns 283,559 shares or 0.02% of their US portfolio. Nomura Asset Mngmt Co holds 0.06% in Incyte Corporation (NASDAQ:INCY) or 39,898 shares. Wetherby Asset Mgmt Incorporated owns 1,851 shares or 0.03% of their US portfolio. Moreover, Numeric Investors Ltd Liability has 0% invested in Incyte Corporation (NASDAQ:INCY). Massachusetts-based Reynders Mcveigh Cap Mngmt Llc has invested 0.03% in Incyte Corporation (NASDAQ:INCY).

Since August 1, 2017, it had 1 insider buy, and 9 sales for $325,377 activity. Trower Paul had sold 3,000 shares worth $375,750 on Thursday, August 3. 1,820 shares were sold by Siegel Eric H., worth $250,068 on Friday, September 1. 2,111 Incyte Corporation (NASDAQ:INCY) shares with value of $263,875 were sold by Stein Steven H. 6,760 shares were sold by GRYSKA DAVID W, worth $668,361. BAKER BROS. ADVISORS LP also bought $13.20 million worth of Incyte Corporation (NASDAQ:INCY) on Friday, September 8. Hoppenot Herve had sold 70,502 shares worth $8.42 million.

Artal Group Sa increased its stake in Incyte Corp (INCY) by 100% based on its latest 2017Q3 regulatory filing with the SEC. Artal Group Sa bought 200,000 shares as the company’s stock rose 9.08% with the market. The institutional investor held 400,000 shares of the commercial physical & biological resarch company at the end of 2017Q3, valued at $46.70 million, up from 200,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Incyte Corp for a number of months, seems to be bullish on the $19.32 billion market cap company. The stock decreased 2.70% or $2.54 during the last trading session, reaching $91.53. About 1.12 million shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since January 16, 2017 and is uptrending. It has outperformed by 56.14% the S&P500.

Artal Group Sa, which manages about $5.81 billion US Long portfolio, decreased its stake in Biomarin Pharmaceutical Inc (Call) (NASDAQ:BMRN) by 50,000 shares to 100,000 shares, valued at $9.31 million in 2017Q3, according to the filing. It also reduced its holding in Nektar Therapeutics (Call) (NASDAQ:NKTR) by 400,000 shares in the quarter, leaving it with 600,000 shares, and cut its stake in Morgan Stanley (Call) (NYSE:MS).

More recent Incyte Corporation (NASDAQ:INCY) news were published by: Seekingalpha.com which released: “Incyte: Low Expectations, Great Growth, Looks Appealing” on January 12, 2018. Also Benzinga.com published the news titled: “Jim Cramer Advises His Viewers On Incyte And American Outdoor Brands” on January 08, 2018. Businesswire.com‘s news article titled: “Incyte and Syros Announce Global Target Discovery and Validation Collaboration …” with publication date: January 08, 2018 was also an interesting one.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 24 analysts covering Incyte (NASDAQ:INCY), 20 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Incyte has $18000 highest and $85 lowest target. $128.71’s average target is 40.62% above currents $91.53 stock price. Incyte had 75 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Incyte Corporation (NASDAQ:INCY) has “Outperform” rating given on Wednesday, October 12 by RBC Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, February 15. The stock of Incyte Corporation (NASDAQ:INCY) earned “Buy” rating by UBS on Wednesday, August 5. Barclays Capital initiated the stock with “Overweight” rating in Thursday, August 13 report. Nomura maintained the shares of INCY in report on Tuesday, October 6 with “Buy” rating. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, November 1. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, October 26 report. The firm has “Outperform” rating by Oppenheimer given on Friday, February 12. As per Friday, July 21, the company rating was maintained by BMO Capital Markets. The rating was upgraded by Raymond James to “Buy” on Monday, September 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.